source
- Cellectis to cut 70% of staff as it shifts focus from allogeneic CAR-T to in vivo gene editingCellectis announced that roughly seven out of ten employees will be let go as the Paris‑based biotech restructures its operations. The company previously abandoned its two clinical‑stage allogenei…
- Clene Nanomedicine partners with Veristat to speed data analysis for ALS drug FDA filingClene Nanomedicine has entered a partnership with clinical research organization Veristat. Under the agreement, Veristat will apply its biostatistics platform to speed the generation and analysis…